Cigarette smoke is strongly associated with affected LHON cases
This IFOND funded study [full text free], part of the ongoing LHON - Brazil Project, for the first time clarifies
the association and mechanism of toxic tobacco smoke on loss of sight in those affected by Leber Hereditary Optic
Neuropathy (LHON): L. Giordano, et al. Cigarette toxicity triggers Leber's
hereditary optic neuropathy by affecting mtDNA copy number, oxidative phosphorylation and ROS detoxification pathways.
Cell Death Dis. 2015 Dec; 6(12): e2021.
Some of their research colleagues have noted that,
rather strikingly, the clinical penetrance of the LHON mtDNA mutations was 93% in the males who smoked compared
to 50% in the literature.
Further research may find further, likely genetic, factors predicting those LHON carriers at higher
risk of becoming affected.
This is but one of many IFOND studies, arising from its sponsorship of the LHON Brazil Project,
devoted to understanding and therapy of LHON.
Use Zelle to donate to our Bank of America account with our email, ifond@aol.com
or
Donate ForGood
or
Donate directly to IFOND at the address below.
Other ways to give:
Stock transfers: Stocks, bonds and similar instruments can be transfered directly to IFOND as donations.
Matching gifts: Many employers will match IFOND donations given by employees.
Gifts in kind: Property, items of appreciable value and service can be donated directly to IFOND.
Legacy, bequests, planned gifts: Make IFOND the beneficiary of your will, insurance policy, bank account, real estate or other.
Gifts of solidarity and remembrance: Bestow a gift to IFOND in honour of a cherished, or important person.
Project specific option: Instruct IFOND which area of research to support with your donation.
The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.
